HURA

TuHURA Biosciences, Inc. (HURA) | Rumor.io

TuHURA Biosciences

HURA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,292

Bullish sentiment (50-day avg)93%

Price to earnings ratio-3.3

Market capitalization133.2M

Earnings per share-0.54

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-30.1M

Social

What share of all stock conversation is about HURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 13

$HURA is in play, with a possible multi-day move.
The company's price target may be reached soon, but some investors are concerned about the potential for insiders to dump shares.
Institutional ownership is high, but some retail investors are skeptical about the company's value and predict a sell-off by end of July.

Generated by AI

Sentiment

Of the messages about HURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.5% -5.4
Bearish	—	—	—	14.5% +5.4

Bullish· Feb 11

$HURA has the potential to reach $3-$5 today, according to current price targets.
The company's recent pipeline and news have been well-received, with one investor seeing a significant gain from a buy at $0.4599.
$HURA is in the middle of a squeeze, which could lead to a pop in price, and is also seeing a natural pullback that could be a buying opportunity.

Bearish· Feb 2

$HURA's price plummeted from 32% to a 52-week low, with some speculating that this is a result of manipulation by the company or an individual.
The stock's rapid decline from $0.75 to $0.55 in a short period suggests a high degree of volatility and potential for further losses.
The bearish sentiment is fueled by concerns of dilution, with some users suggesting that the company is diluting its shares to enrich itself, leading to a predicted drop below 50 cents.

Generated by AI

Topics

Of the messages about HURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	75.12%
Technical Analysis	—	—	0%	17.06%
Analysts	—	—	0%	0.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.24%
Macro	—	—	0%	6.87%

Announcements· Oct 7

Global X Uranium index ETF (HURA) is 100% invested in the uranium sector.
The last commercially available lbs of uranium will become unavailable before being sold.
The uranium sector is facing a shortage of available pounds.

Technical Analysis· Apr 3

$HURA is showing a bullish pennant pattern and an inverse head and shoulders pattern, indicating a potential breakout above $0.18.
The stock has been experiencing strong consolidation, with a 75M volume spike, and is expected to move higher from here.
The 1m chart is displaying a series of green candles, indicating an uptrend, with some analysts predicting a potential top at $0.2632, the previous daily high.

Generated by AI

Community

Of the messages about HURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	66.67%	75%	20.53%
Newcomers	100%	33.33%	25%	79.47%

Feb 2

TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma, a significant development that could lead to market exclusivity and reduced regulatory requirements.
The FDA designation is based on Phase 1 data showing the safety and efficacy of IFx-2.0 in checkpoint-inhibitor-refractory patients, and could potentially add 7 years of U.S. market exclusivity.
Shares of TuHURA Biosciences have seen a significant increase in price, up ~37% on the news, and some analysts are speculating about the potential for further growth.

Generated by AI

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

15d agoYahoo Finance

TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia

TuHURA Biosciences (HURA) said Monday that the US Food and Drug Administration has cleared its inves

16d agoYahoo Finance

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

22d agoYahoo Finance

HURA: Milestone Progression Over Next 12 Months

By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On August 14 th , 2026, TuHURA Biosciences, Inc. (NASDAQ: HURA) reported 2Q:26 financial and operational results and filed its Form 10-Q with the SEC. There have been several updates since the previous update in May, most notably the filing of the Investigational New Drug (IND) application

1mo agoYahoo Finance

Also Discussed

Investors talking about HURA also mention

#	Name	Attention
1	EGOX - Next.e.GO N.V. Ordinary Shares	——
2	ROI - RiskOn International, Inc.	——
3	ATAK - Aurora Technology Acquisition Corp.	——
4	Crown Electrokinetics Corp.CRKN	0%0
5	Femto Technologies Inc.BCAN	0%0
6	TPHS - Trinity Place Holdings Inc.	——
7	Estrella Immunopharma, Inc.ESLA	0%0
8	SLNA - Selina Hospitality PLC	——
9	Gaucho Group Holdings, Inc.VINO	0%0
10	Greenwave Technology Solutions, Inc.GWAV	0%0

TuHURA Biosciences, Inc.

Healthcare
Biotechnology

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, including IFx-2.0, an innate immune agonist intended to enhance responses to checkpoint inhibitors, and additional technologies aimed at addressing both primary and acquired resistance in the tumor microenvironment. TuHURA Biosciences also works on personalized cancer vaccines and bi-functional antibody-drug conjugates that target immune-suppressing cells linked to treatment resistance. Based in Tampa, Florida, TuHURA Biosciences operates in the biotechnology and oncology drug development sectors, where its programs are intended to support combination approaches for difficult-to-treat cancers and advance late-stage clinical research in immunotherapy.

Website

Location

10500 University Center Drive

Tampa, FL, 33612

United States

Social

What share of all stock conversation is about HURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 13

$HURA is in play, with a possible multi-day move.
The company's price target may be reached soon, but some investors are concerned about the potential for insiders to dump shares.
Institutional ownership is high, but some retail investors are skeptical about the company's value and predict a sell-off by end of July.

Generated by AI

Sentiment

Of the messages about HURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.5% -5.4
Bearish	—	—	—	14.5% +5.4

Bullish· Feb 11

$HURA has the potential to reach $3-$5 today, according to current price targets.
The company's recent pipeline and news have been well-received, with one investor seeing a significant gain from a buy at $0.4599.
$HURA is in the middle of a squeeze, which could lead to a pop in price, and is also seeing a natural pullback that could be a buying opportunity.

Bearish· Feb 2

$HURA's price plummeted from 32% to a 52-week low, with some speculating that this is a result of manipulation by the company or an individual.
The stock's rapid decline from $0.75 to $0.55 in a short period suggests a high degree of volatility and potential for further losses.
The bearish sentiment is fueled by concerns of dilution, with some users suggesting that the company is diluting its shares to enrich itself, leading to a predicted drop below 50 cents.

Generated by AI

Topics

Of the messages about HURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	75.12%
Technical Analysis	—	—	0%	17.06%
Analysts	—	—	0%	0.71%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.24%
Macro	—	—	0%	6.87%

Announcements· Oct 7

Global X Uranium index ETF (HURA) is 100% invested in the uranium sector.
The last commercially available lbs of uranium will become unavailable before being sold.
The uranium sector is facing a shortage of available pounds.

Technical Analysis· Apr 3

$HURA is showing a bullish pennant pattern and an inverse head and shoulders pattern, indicating a potential breakout above $0.18.
The stock has been experiencing strong consolidation, with a 75M volume spike, and is expected to move higher from here.
The 1m chart is displaying a series of green candles, indicating an uptrend, with some analysts predicting a potential top at $0.2632, the previous daily high.

Generated by AI

Community

Of the messages about HURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	66.67%	75%	20.53%
Newcomers	100%	33.33%	25%	79.47%

Feb 2

TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma, a significant development that could lead to market exclusivity and reduced regulatory requirements.
The FDA designation is based on Phase 1 data showing the safety and efficacy of IFx-2.0 in checkpoint-inhibitor-refractory patients, and could potentially add 7 years of U.S. market exclusivity.
Shares of TuHURA Biosciences have seen a significant increase in price, up ~37% on the news, and some analysts are speculating about the potential for further growth.

Generated by AI

TuHURA Biosciences

Social

Apr 13

Sentiment

Bullish· Feb 11

Bearish· Feb 2

Topics

Announcements· Oct 7

Technical Analysis· Apr 3

Community

Feb 2

News

Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress

TuHURA receives FDA clearance for leukemia drug trial

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HURA: Milestone Progression Over Next 12 Months

Also Discussed

TuHURA Biosciences, Inc.

Company Information

Location

News

Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress

TuHURA receives FDA clearance for leukemia drug trial

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HURA: Milestone Progression Over Next 12 Months

Also Discussed

Social

Apr 13

Sentiment

Bullish· Feb 11

Bearish· Feb 2

Topics

Announcements· Oct 7

Technical Analysis· Apr 3

Community

Feb 2